PCDHGB1: A Potential Drug and Biomarker Target (G56104)

Target Name: PCDHGB1

NCBI ID: G56104

PCDHGB1

PCDHGB1: A Potential Drug and Biomarker Target

PCDHGB1 (Protocadherin gamma subfamily B, 1, isoform 2) is a protein that is expressed in various tissues throughout the body. It is a member of the Protocadherin gene family, which is known for its role in cell-cell adhesion. PCDHGB1 is one of the isoforms of the PCDHGB1 gene, which has been shown to be involved in the development and maintenance of various tissues and organs, including neural cells, heart cells, and blood vessels.

The Importance of PCDHGB1

PCDHGB1 is a critical protein that plays a vital role in the development and maintenance of many tissues and organs. One of its most important functions is to help maintain the integrity of the intercellular junctions, which are the weak bonds that hold cells together and allow them to communicate with one another. These junctions are critical for the proper functioning of tissues and organs, and problems with them can lead to a range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

PCDHGB1 is also involved in the regulation of cell growth and differentiation. It helps to ensure that cells are properly organized and that they have the necessary signaling mechanisms to divide and grow. In addition, PCDHGB1 is involved in the development and maintenance of tissues and organs, including the brain and spinal cord.

PCDHGB1 as a Drug Target

PCDHGB1 has been identified as a potential drug target for a variety of diseases. For example, some studies have suggested that PCDHGB1 may be a useful target for treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can be treated with a variety of drugs, including neuroprotective agents and disease-modifying therapies. However, many of these drugs are limited in their effectiveness and can have significant side effects.

In addition to its potential use in neurodegenerative diseases, PCDHGB1 has also been suggested as a potential target for treating other conditions, including cancer and cardiovascular diseases. For example, some studies have suggested that PCDHGB1 may be a useful target for treating breast cancer, by inhibiting its ability to promote cell growth and division. In addition, PCDHGB1 has been shown to be involved in the regulation of blood vessel diameter and blood pressure, which may make it a useful target for treating cardiovascular diseases.

PCDHGB1 as a Biomarker

PCDHGB1 has also been suggested as a potential biomarker for a variety of diseases. For example, some studies have suggested that PCDHGB1 may be a useful biomarker for the diagnosis and prognosis of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can be treated with a variety of drugs, including neuroprotective agents and disease-modifying therapies. However, many of these drugs are limited in their effectiveness and can have significant side effects.

In addition to its potential use as a drug target, PCDHGB1 has also been suggested as a potential biomarker for other conditions, including cancer and cardiovascular diseases. For example, some studies have suggested that PCDHGB1 may be a useful biomarker for the diagnosis and prognosis of breast cancer, by inhibiting its ability to promote cell growth and division. In addition, PCDHGB1 has been shown to be involved in the regulation of blood vessel diameter and blood pressure, which may make it a useful biomarker for

Protein Name: Protocadherin Gamma Subfamily B, 1

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets